Physiologically Based Pharmacokinetic Modeling to Investigate the Disease-Drug-Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID-19 Patients with CYP2C19 Phenotypes
In conclusion, COVID-19-induced IL-6 elevation and ritonavir increased voriconazole exposure, and the magnitude of interactions was influenced by CYP2C19 phenotype. Thus, caution is warranted when prescribing voriconazole concomitantly with Paxlovid in patients with COVID-19.PMID:38429919 | DOI:10.1002/cpt.3222 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - March 2, 2024 Category: Drugs & Pharmacology Authors: Peile Wang Shuaibing Liu Jing Yang Source Type: research
Physiologically Based Pharmacokinetic Modeling to Investigate the Disease-Drug-Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID-19 Patients with CYP2C19 Phenotypes
In conclusion, COVID-19-induced IL-6 elevation and ritonavir increased voriconazole exposure, and the magnitude of interactions was influenced by CYP2C19 phenotype. Thus, caution is warranted when prescribing voriconazole concomitantly with Paxlovid in patients with COVID-19.PMID:38429919 | DOI:10.1002/cpt.3222 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - March 2, 2024 Category: Drugs & Pharmacology Authors: Peile Wang Shuaibing Liu Jing Yang Source Type: research
Longer-term Outcomes in Critically Ill Patients with COVID-19 in the REMAP-CAP Trial
Clinical question: What is the longer-term (180-day) mortality effect of common therapies on critically ill patients with COVID-19?
Background: Most randomized clinical trials for patients with COVID-19 focus on short-term outcomes such as 28-day mortality or organ failure. Trials evaluating longer-term outcomes of therapeutic interventions are needed.
Study design: Randomized adaptive-platform trial
Setting: International multicenter trial (197 sites in 14 countries)
Synopsis: 4,869 critically ill patients were enrolled from March 2020 through June 2021. Patients were randomized to one of six treatment arms (immune modula...
Source: The Hospitalist - March 1, 2024 Category: Hospital Management Authors: Ronda Whitaker Tags: COVID-19 In the Literature Source Type: research
Development and characterization of solid lipid-based formulations (sLBFs) of ritonavir utilizing a lipolysis and permeation assay
In this study, ritonavir loaded solid LBFs (sLBFs) were prepared using solid lipid excipients to investigate whether sLBFs are also capable of improving solubility and permeability. Additionally, the influence of polymeric precipitation inhibitors (PVP-VA and HPMC-AS) on lipolysis triggered supersaturation and precipitation was investigated. One step intestinal digestion and bicompartmental permeation studies using an artificial lecithin-in-dodecane (LiDo) membrane were performed for each formulation. All formulations presented significantly higher solubility (5 to >20-fold higher) during lipolysis and permeation studie...
Source: European Journal of Pharmaceutical Sciences - February 26, 2024 Category: Drugs & Pharmacology Authors: Arne Schulzen Ioannis I Andreadis Christel A S Bergstr öm Julian Quodbach Source Type: research
Development and characterization of solid lipid-based formulations (sLBFs) of ritonavir utilizing a lipolysis and permeation assay
In this study, ritonavir loaded solid LBFs (sLBFs) were prepared using solid lipid excipients to investigate whether sLBFs are also capable of improving solubility and permeability. Additionally, the influence of polymeric precipitation inhibitors (PVP-VA and HPMC-AS) on lipolysis triggered supersaturation and precipitation was investigated. One step intestinal digestion and bicompartmental permeation studies using an artificial lecithin-in-dodecane (LiDo) membrane were performed for each formulation. All formulations presented significantly higher solubility (5 to >20-fold higher) during lipolysis and permeation studie...
Source: European Journal of Pharmaceutical Sciences - February 26, 2024 Category: Drugs & Pharmacology Authors: Arne Schulzen Ioannis I Andreadis Christel A S Bergstr öm Julian Quodbach Source Type: research
Management of SARS-CoV-2 and Persistent Viral Detection in Solid Organ Transplant Recipients
AbstractPurpose of ReviewWe explore the challenges of managing solid organ transplant recipients (SOTRs) during the COVID-19 pandemic, with a focus on prolonged viral detection in immunosuppressed individuals.Recent FindingsSOTR guidelines recommend three mRNA vaccine doses with additional booster dosing and continued protective post-vaccination measures. COVID-19 therapies are similar for SOTRs and non-SOTRs, although drug-drug interactions limit the use of some such as nirmatrelvir/ritonavir (NIM-RTV). Inpatient treatment options include remdesivir and steroids; outpatient antiviral options include NIM-RTV or remdesivir....
Source: Current Respiratory Care Reports - February 24, 2024 Category: Respiratory Medicine Source Type: research
Simnotrelvir as a potential treatment for COVID-19
Expert Opin Pharmacother. 2024 Feb 23. doi: 10.1080/14656566.2024.2323597. Online ahead of print.ABSTRACTINTRODUCTION: Simnotrelvir is a selective 3-chymotrypsin-like oral protease inhibitor with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).AREAS COVERED: On 18 January 2024, results of a double-blind, randomized, placebo-controlled trial of simnotrelvir as a treatment for mild-to moderate COVID-19-were published, indicating the drug, when given in combination with ritonavir, shortened the time to resolution of symptoms.EXPERT OPINION: Treatment options for most outpatients with mild-to-mode...
Source: Expert Opinion on Pharmacotherapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Matthew W McCarthy Source Type: research
Simnotrelvir as a potential treatment for COVID-19
Expert Opin Pharmacother. 2024 Feb 27:1-5. doi: 10.1080/14656566.2024.2323597. Online ahead of print.ABSTRACTINTRODUCTION: Simnotrelvir is a selective 3-chymotrypsin-like oral protease inhibitor with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).AREAS COVERED: On 18 January 2024, results of a double-blind, randomized, placebo-controlled trial of simnotrelvir as a treatment for mild-to moderate COVID-19-were published, indicating the drug, when given in combination with ritonavir, shortened the time to resolution of symptoms.EXPERT OPINION: Treatment options for most outpatients with mild-to-...
Source: Expert Opinion on Pharmacotherapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Matthew W McCarthy Source Type: research
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers
ConclusionThis trial with three microdosed FXaI suggests that at most the rivaroxaban dose should be reduced during short-term ritonavir, and only in patients receiving high maintenance doses. Thorough time series analyses demonstrated differential effects on three different drug-metabolising enzymes over time with immediate profound inhibition of CYP3A4 and only slow recovery after discontinuation.Clinical Trial RegistrationEudraCT number: 2021-006643-39. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19
CONCLUSION: In conclusion, our findings suggest that similar to nirmatrelvir-ritonavir, molnupiravir has a distinct potential role in COVID-19 treatment, transcending its current perceived status as only a secondary option.PMID:38374626 | DOI:10.3346/jkms.2024.39.e52 (Source: Journal of Korean Medical Science)
Source: Journal of Korean Medical Science - February 20, 2024 Category: Biomedical Science Authors: Young Rock Jang Yoonju Oh Jin Yong Kim Source Type: research
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19
CONCLUSION: In conclusion, our findings suggest that similar to nirmatrelvir-ritonavir, molnupiravir has a distinct potential role in COVID-19 treatment, transcending its current perceived status as only a secondary option.PMID:38374626 | DOI:10.3346/jkms.2024.39.e52 (Source: J Korean Med Sci)
Source: J Korean Med Sci - February 20, 2024 Category: General Medicine Authors: Young Rock Jang Yoonju Oh Jin Yong Kim Source Type: research
